CUAMC
NRXP icon

China Universal Asset Management Company’s NRX Pharmaceuticals NRXP Stock Holding History

China Universal Asset Management Company’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-63
Closed – – 434
2022
Q3 		$0 Buy
+63
New +$425 ﹤0.01% 452

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

China Universal Asset Management Company's NRXP Position: Q4 2022 in Review

China Universal Asset Management Company sold out of NRX Pharmaceuticals (NRXP) in Q4 2022, closing a stake of 63 shares.

China Universal Asset Management Company first reported a position in NRXP in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 33 funds tracked by Wall St. Rank hold NRXP as of Q4 2022.

  • China Universal Asset Management Company reported no remaining NRX Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • China Universal Asset Management Company sold 63 NRX Pharmaceuticals shares in Q4 2022.
  • China Universal Asset Management Company first reported a position in NRX Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • China Universal Asset Management Company's NRX Pharmaceuticals position peaked at $0 in Q3 2022.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.